Literature DB >> 33888024

Value, Limitations, and Recommendations for Grading of Canine Cutaneous Mast Cell Tumors: A Consensus of the Oncology-Pathology Working Group.

Davide Berlato1, Julie Bulman-Fleming2, Craig A Clifford3, Laura Garrett4, Joanne Intile5, Pamela Jones6, Debra A Kamstock7, Julius M Liptak8, Alana Pavuk9, Roger Powell10, Roberta Rasotto11.   

Abstract

One of the primary objectives of the Oncology Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects and provide guidelines for oncologic pathology. Consensus is established through review of relevant peer-reviewed literature relative to a subgroup's particular focus. In this article, the authors provide a critical review of the current literature for grading of canine cutaneous mast cell tumors, suggest guidelines for reporting, and provide recommendations for its clinical interpretation. The article mainly focuses on histologic grading, but relevant information on mitotic count and cytological grading are also discussed. This document represents the opinions of the working group and the authors but does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.

Entities:  

Keywords:  cancer; dogs; grading; mast cell tumor; oncology; pathology

Year:  2021        PMID: 33888024     DOI: 10.1177/03009858211009785

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  5 in total

1.  Τhe Effect of Opioid Administration on Cytologic and Histopathologic Diagnosis of Canine Cutaneous Mast Cell Tumors Treated by Surgical Excision.

Authors:  Christina Marouda; Tilemahos Anagnostou; Ioannis Savvas; Lysimachos G Papazoglou; Dimitra Psalla
Journal:  Vet Sci       Date:  2022-04-22

Review 2.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

3.  Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Authors:  Shawna Klahn; Nikolaos Dervisis; Kevin Lahmers; Marian Benitez
Journal:  Vet Sci       Date:  2022-06-07

4.  Sentinel Lymph Node Mapping with Indirect Lymphangiography for Canine Mast Cell Tumour.

Authors:  Andrea De Bonis; Francesco Collivignarelli; Andrea Paolini; Ilaria Falerno; Valentina Rinaldi; Roberto Tamburro; Amanda Bianchi; Rossella Terragni; Jacopo Gianfelici; Paolo Frescura; Giulia Dolce; Eleonora Pagni; Roberta Bucci; Massimo Vignoli
Journal:  Vet Sci       Date:  2022-09-08

5.  Vet-ICD-O-Canine-1, a System for Coding Canine Neoplasms Based on the Human ICD-O-3.2.

Authors:  Katia Pinello; Valeria Baldassarre; Katja Steiger; Orlando Paciello; Isabel Pires; Renée Laufer-Amorim; Anna Oevermann; João Niza-Ribeiro; Luca Aresu; Brian Rous; Ariana Znaor; Ian A Cree; Franco Guscetti; Chiara Palmieri; Maria Lucia Zaidan Dagli
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.